

# Juraj Bodo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4783421/publications.pdf>

Version: 2024-02-01

19  
papers

453  
citations

1040056

9  
h-index

888059

17  
g-index

19  
all docs

19  
docs citations

19  
times ranked

747  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                                                                                                                                                              | IF  | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1  | Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. <i>Cell Death and Disease</i> , 2020, 11, 941.                                                                                                                                                                                                                                         | 6.3 | 115       |
| 2  | Combination of ibrutinib with <sc>ABT</sc>â€199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of <sc>BTK</sc>, <sc>AKT</sc> and <sc>BCL</sc>2 pathways. <i>British Journal of Haematology</i> , 2015, 168, 765-768.                                                                              | 2.5 | 75        |
| 3  | Acquired resistance to venetoclax (ABT-199) in<i>t(14;18)</i> positive lymphoma cells. <i>Oncotarget</i> , 2016, 7, 70000-70010.                                                                                                                                                                                                                                     | 1.8 | 59        |
| 4  | Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. <i>Cell Death and Disease</i> , 2019, 10, 924.                                                                                                                                                                | 6.3 | 51        |
| 5  | Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. <i>Cancer Research</i> , 2020, 80, 2031-2044.                                                                                                                                                                                                   | 0.9 | 36        |
| 6  | The phosphatidylinositol 3â€kinases (<sc>PI</sc>3<sc>K</sc>) inhibitor <sc>GS</sc>â€1101 synergistically potentiates histone deacetylase inhibitorâ€induced proliferation inhibition and apoptosis through the inactivation of <sc>PI</sc>3<sc>K</sc> and extracellular signalâ€regulated kinase pathways. <i>British Journal of Haematology</i> , 2013, 163, 72-80. | 2.5 | 28        |
| 7  | CCMCL1: a new model of aggressive mantle cell lymphoma. <i>Blood</i> , 2015, 125, 2730-2732.                                                                                                                                                                                                                                                                         | 1.4 | 17        |
| 8  | CAL2 Immunohistochemical Staining Accurately Identifies<i>CALR</i> Mutations in Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2016, 146, 431-438.                                                                                                                                                                                    | 0.7 | 17        |
| 9  | HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2011, 16, 914-923.                                                                                                                                                                                           | 4.9 | 13        |
| 10 | SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. <i>British Journal of Haematology</i> , 2019, 185, 145-147.                                                                                                                                                                                   | 2.5 | 9         |
| 11 | Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas. <i>American Journal of Clinical Pathology</i> , 2020, 153, 646-655.                                                                                                                                                 | 0.7 | 9         |
| 12 | Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies. <i>Cell Death and Disease</i> , 2021, 12, 1061.                                                                                                                                                                                                     | 6.3 | 8         |
| 13 | Immune Escape Mechanisms in Intravascular Large B-Cell Lymphoma: A Molecular Cytogenetic and Immunohistochemical Study. <i>American Journal of Clinical Pathology</i> , 2022, 157, 578-585.                                                                                                                                                                          | 0.7 | 5         |
| 14 | Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 351-359.                                                                                                                                                                                            | 2.5 | 5         |
| 15 | Inhibition of cyclinâ€dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma. <i>EJHaem</i> , 2020, 1, 161-169.                                                                                                                                                                                                                     | 1.0 | 2         |
| 16 | Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis. <i>Human Pathology</i> , 2021, 107, 1-8.                                                                                                                                                                                                           | 2.0 | 2         |
| 17 | Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity. <i>Journal of Clinical Pathology</i> , 2022, 75, 636-642.                                                                                                                                                    | 2.0 | 2         |
| 18 | Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab. <i>Blood</i> , 2019, 134, 1515-1515.                                                                                                                                                                                                 | 1.4 | 0         |

| #  | ARTICLE                                                                                                                                                                                              | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations. Blood, 2019, 134, 1572-1572. | 1.4 | 0         |